Study of ASP1948, Targeting an Immune Modulatory Receptor, in Japanese Patients with Advanced Solid Tumors

Trial Identifier: 1948-CL-0102
Sponsor: Astellas Pharma Inc.
Start Date: October 2019
Primary Completion Date: February 2022
Study Completion Date: February 2022

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description

Trial Locations

Country Location
Japan, Tokyo Chuo-ku, Tokyo, Japan